India's home grown JE vaccine pares dependence on China
This article was originally published in Scrip
India has launched its first fully indigenous Japanese encephalitis (JE) vaccine, developed under a three-way public-private partnership and which is expected to pare the country's current dependence on supplies from China.
You may also be interested in...
Years after a scathing Indian parliamentary report flagged concerns around regulatory lapses for drug approvals, an expert panel has endorsed the continued marketing of ambrisentan and everolimus in the country. But dronedarone, also featured in the report, is no longer sold by Sanofi in India.
Tecentriq cleared for extensive-stage small cell lung cancer in India but pricing remains a key constraining factor. Patient assistance schemes help but such novel therapies still unaffordable to a vast majority.